Trial Profile

A multi-arm non-comparative signal seeking phase II platform umbrella trial of biomarker-directed novel second-line treatments in metastatic pancreatic cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 10 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceralasertib (Primary) ; Olaparib (Primary)
Indications Adenocarcinoma; Cancer metastases; Pancreatic ductal carcinoma
Focus Therapeutic Use
Acronyms PRIMUS-004

Most Recent Events

10 Jan 2024 Status changed from recruiting to discontinued.
29 Jul 2020 Status changed from not yet recruiting to recruiting.
29 Jul 2020 Planned initiation date changed changed from 01 Jul 2020 to 01 Sep 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com